Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College, Ucb Biopharma SprlfiledCriticalHarvard College
Publication of AR104501A1publicationCriticalpatent/AR104501A1/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
Anticuerpos anti-AP2 y agentes de unión al antígeno mejorados, y composiciones de los mismos, dirigidos a la chaperona de lípido aP2/FABP4 (denominado aP2) que son de utilidad en el tratamiento de trastornos tales como diabetes, obesidad, enfermedad cardiovascular, enfermedad de hígado graso y/o cáncer, entre otros. En un aspecto, se divulgan tratamientos mejorados para trastornos mediados por aP2 en donde el blanco es la aP2 en suero y la actividad biológica de aP2 se neutraliza o modula usando anticuerpos monoclonales anti-aP2 de afinidad de unión baja, lo cual proporciona niveles más bajos de glucosa en sangre en ayuno, un metabolismo sistémico de glucosa mejorado, mayor sensibilidad sistémica a la insulina, masa de grasas reducida, esteatosis hepática reducida, enfermedad cardiovascular reducida y/o un riesgo reducido de desarrollar una enfermedad cardiovascular.Improved anti-AP2 antibodies and antigen binding agents, and compositions thereof, directed to the lipid chaperone aP2 / FABP4 (called aP2) that are useful in the treatment of disorders such as diabetes, obesity, cardiovascular disease, disease of fatty liver and / or cancer, among others. In one aspect, improved treatments for aP2-mediated disorders are reported where the target is serum aP2 and the biological activity of aP2 is neutralized or modulated using anti-aP2 monoclonal antibodies of low binding affinity, which provides lower levels. fasting blood glucose, an improved systemic glucose metabolism, increased systemic insulin sensitivity, reduced fat mass, reduced liver steatosis, reduced cardiovascular disease and / or a reduced risk of developing cardiovascular disease.
ARP160101244A2015-04-302016-05-02
ANTI-AP2 ANTIBODIES AND ANTIGEN BINDING AGENTS TO TREAT METABOLIC DISORDERS
AR104501A1
(en)
Nε-(carboxymethyl) lysine-receptor for advanced glycation end product axis is a key modulator of obesity-induced dysregulation of adipokine expression and insulin resistance
Maintenance of the musculoskeletal mass by control of protein turnover: the concept of anabolic resistance and its relevance to the transplant recipient.
Median-lower normal levels of serum thyroxine are associated with low triiodothyronine levels and body temperature in patients with central hypothyroidism